Role of neuropeptides in antidepressant and memory improving effects of venlafaxine

Polish Journal of Pharmacology

Volumn 54, Issue 6, 2002, Pages 605-613

  Nowakowska, Elzbieta ^a   Kus, Krzysztof ^a   Bobkiewicz Kozłowska, Teresa ^a   Hertmanowska, Hanka ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Department of Urology   (Poland)

Author keywords

Behavioral effects; Oxytocin; Rats; Vasopressin; Venlafaxine

Indexed keywords

ANTIDEPRESSANT AGENT; ARGIPRESSIN; BETA ADRENERGIC RECEPTOR; BITOLTEROL MESILATE; CITALOPRAM; DOPAMINE; NEUROPEPTIDE; NORADRENALIN; OXYTOCIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; VASOPRESSIN; VENLAFAXINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; MALE; MAZE TEST; MONOAMINERGIC SYSTEM; MOOD; NONHUMAN; PROTEIN FUNCTION; RAT; SPATIAL MEMORY; SWIMMING; WORKING MEMORY;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; IMMOBILIZATION; MALE; MEMORY; NEUROPEPTIDES; NOOTROPIC AGENTS; RATS; RATS, WISTAR;

EID: 0036968107     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Altemus M., Pigott T., Kalogeras K.T., Demitrack M., Dubbert B., Murphy D.L., Gold P.W: Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder. Arch. Gen. Psychiat., 1992, 49, 9-20.
2. Arletti R., Bertolini A.: Oxytocin acts as an antidepressant in two animal models of depression. Life Sci., 1987, 41, 1725-1730.
3. Bluthe R.M., Dantzer R.: Social recognition does not involve vasopressinergic neurotransmission in female rats. Brain Res., 1990, 535, 301-304.
4. Brinton R.: Neuromodulation: associative and nonlinear adaptation. Brain Res. Bull., 1990, 24, 651-658.
5. De Bellis M.D., Gold P.W., Geracioti T.D., Listwak S.J., Kling M.A.: Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine-vasopressin in patients with major depression. Amer. J. Psychiat., 1993, 150, 656-657.
6. Del Pozo E., Martin-Perez J., Stadelmann A., Girard J., Brownell J.: Inhibitory action of a met-enkephalin on ACTH release in man. J. Clin. Invest., 1980, 65, 1531-1534.
7. de Wied D.: Neurohypophyseal hormones influences on learning and memory processes. In: Neurobiology of Learning and Memory. Eds. Lynch G., McGaugh J., Weinberger N.M., Guildford Press, New York, 1984, 289-312.
8. de Wied D., Elands J., Kovacs G.: Interactive effects of neurohypophyseal neuropeptides with receptor antagonists on passive avoidance behavior: mediation by a cerebral neurohypophyseal hormone receptor? Proc. Nat. Acad. Sci. USA, 1991, 88, 1492-1498.
9. de Wied D., van Ree J.M.: Neuropeptides: animal behaviour and human psychopathology. Eur. Arch. Psychiat. Clin. Neuros., 1989, 238, 323-331.
10. Dockray G.J.: Immunological evidence of cholecystokinin-like peptides in brain. Nature, 1976, 264, 568-572.
11. Engelmann M., Ebner K., Wotjak C.T., Landgraf R.: Endogenous oxytocin is involved in short-term olfactory memory in female rats. Behav. Brain Res., 1998, 80, 89-94.
12. Engelmann M., Landgraf R.: Microdialysis administration of vasopressin into the septum improves social recognition in Brattleboro rats. Physiol. Behav., 1994, 55, 145-149.
13. Fabre L.F., Puthman H.P.: An ascending single-dose tolerance study of Wy-45,030, a bicyclic antidepressant, in healthy men. Curr. Ther. Res., 1987, 42, 901-909.
14. Gold P.W., Post R.M., Weingartner H., Goodwin F.K.: Central peptide function in affective illness: arginine-vasopressin as a model system. Adv. Biol. Psychiat., 1981, 42, 41-70.
15. Gold P.W., Weingartner H. Ballenger J.C., Goodwin F.K., Post R.M.: Effects of 1-desamo-8-D-arginine vasopressin on behaviour and cognition in primary affective disorder. Lancet, 1979, 2, 992-994.
16. Hlinak Z.: Social recognition in ovariectomized and estradiol-treated female rats. Hormone Behav., 1993, 27, 159-166.
17. Kovacs G., Bohus B., Versteeg D.H.: Facilitation of memory consolidation by vasopressin: mediation by terminals of the dorsal noradrenergic bundle? Brain Res., 1979, 172, 73-85.
18. Kovacs G.L., Bohus B., Versteeg D.H., de Kloet E.R., de Wied D.: Effect of oxytocin and vasopressin on memory consolidation: sites of action and catecholaminergic correlates after local microinjection into limbic-midbrain structures. Brain Res., 1979, 175, 303-314.
19. Meisenberg G.: Short-term behavioral effects of posterior pituitary peptides in mice. Peptides, 1981, 2, 1-8.
20. Meisenberg G.: Short-term behavioural effects of neurohypophyseal hormones: pharmacological characteristics. Neuropharmacology, 1982, 21, 309-316.
21. Montgomery S.A.: Rapid onset of action of venlafaxine. Int. Clin. Psychopharmacol., 1995, 10, 21-27.
22. Morris R.: Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Meth., 1994, 11, 47-60.
23. Muth E.A., Moyer J.A., Haskins J.T., Andree T.H., Husbands G.E.M.: Biochemical, neuropsychological and behavioural effects of Wy-45-233 and other identified metabolites of the antidepressant venlafaxine. Drug Develop. Res., 1991, 23, 191-199.
24. Nalepa I., Vetulani J.: β-Down-regulation induced by repeated vasopressin treatment. Eur. J. Pharmacol., 1990, 178, 375-376.
25. Nowakowska E., Kus. K., Chodera A.: Comparison of behavioural effects of venlafaxine and imipramine in rats. Arzneim.-Forsch.-Drug Res., 2002, in press.
26. Poban V., Alescio-Lautier B., Devigne C., Soumireu-Mourat B.: The behavioral effect of vasopressin in the ventral hippocampus is antagonized by an oxytocin receptor antagonist. Eur. J. Pharmacol., 1998, 361, 165-173.
27. Porsolt R.D., Anton G., Blavet N., Jalfre M.: Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol., 1978, 47, 379-391.
28. Rogóz Z., Dziedzicka-Wasylewska M., Maj J.: Pharmacological profile of venlafaxine, a new antidepressant, given acutely. Pol. J. Pharmacol., 1998, 50, 107-115.
29. Saletu B., Brünberger J., Anderer P., Linzmayer L., Semlitsch H.V., Magni G.: Pharmacodynamics of venlafaxine evaluated by EGG brain mapping, psychometry and psychophysiology. Brit. J. Clin. Pharmacol., 1992, 33, 589-601.
30. Uvnas-Moberg K., Bjokstrand E., Hilleggart V., Ahlenius S.: Oxytocin as a possible mediator of SSRI-induced antidepressant effects. Psychopharmacology, 1999, 142, 95-101.
31. van Winersma-Greidanus T.B., Burbach J.P., Veldhuis H.D.: Vasopressin and oxytocin. Their presence in the central nervous system and their functional significance in brain processes related to behaviour and memory. Acta Endocrinol. Suppl., 1986, 276, 85-94.
32. van Winersma-Greidanus T.B., van Ree J.M., Versteeg D.H.G.: Neurohypophyseal peptides and avoidance behaviour: the involvement of vasopressin and oxytocin in memory processes. In: Neuropeptides and Neural Transmission. Eds. Marsan C.A., Traczyk W.Z., Raven Press, New York, 1980, 293-300.